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Abstract
Background: There is limited evidence concerning the relationship between vascular disease and health-related
quality of life (HRQL). We investigated the relationship between vascular structure and function with health-related
quality of life in a population with intermediate cardiovascular risk.
Methods: This study analyzed 303 subjects with ankle-brachial index (ABI) values ranging from 0.9 to 1.4 who were
included in the MARK study (age 35 to 74 years; mean:60.5 ± 8.5), of which 50.2 % were women. Measurements
included: ABI, brachial-ankle pulse wave velocity (ba-PWV), and cardio-ankle vascular index (CAVI), all measured
using the VaSera device. The central augmentation index was adjusted to 75 lpm (AIx_75) using the Mobil-O-Graph
device. HRQL was assessed by the Spanish version of the SF-12, version2. The highest obtained CAVI and ba-PWV
values and the lowest ABI values were considered for the study.
Results: The cohort was composed of21 % smokers, 76 % hypertensive patients, and 24 % diabetic patients. The
ABI mean was 1.09 ± 0.07,the ba-PWV mean was 14.64 ± 2.55 m/s with a 12.9 % of subjects higher than 17.5 m/s,
AIx_75 26.46 ± 14.05, and CAVI 8.61 ± 1.08 with a 36.6 % of subjects higher than 9. Men scored higher than women
in the HRQL measurements for physical (PSC-12; 49.9 vs. 46.9, p = 0.004) and mental (MSC-12) domains (51.2 vs. 47.7,
p = 0.003). Age was positively correlated with CAVI (r = 0.547), ba-PWV (r = 0.469), AIx_75 (r = 0.255, p < 0.01), and the
MSC-12 (r = 0.147, p < 0.05), but not the PSC-12. In the adjusted multiple linear regression analysis, the positive
association of ABI and CAVI with the PSC-12 was maintained.
Conclusions: The ABI in the normal range has a positive association with the PSC-12 of HRQL evaluated with the
SF-12. The CAVI also showed a positive association with the PSC-12 of HRQL.
Trial Registration: ClinicalTrials.gov Identifier: NCT01428934.
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Background
Health outcomes reported by patients are becoming
more important in research, clinical practice, and health
planning [1, 2]. Self-perception of health status and
health-related quality of life (HRQL) provide information
that complements traditional health indicators based on
morbidity and mortality [3]. HRQL is an important out-
come in clinical trials, population health assessments,
clinical improvement, and documenting for purchasers
quality of care. In addition to the more objective clinical
measures, many patients consider HRQL equally import-
ant. HRQL is conceptualized as a patient's perceptions
of the impact of disease and treatment on functioning in
a variety of dimensions, including physical, mental, and
social domains [4, 5]. One of the most commonly used
instruments to measure HRQL is the SF-36 Question-
naire or its SF-12 version [3, 6], that reduces the work-
load of health workers, the workload for patients, and
the time to complete the questionnaire.
The assessment of vascular structure and function
with different devices allows for the detection of the
early stages of atherosclerosis and the degree of arterial
stiffness. Fowkes et al. conducted a meta-analysis of 16
population cohort studies that included 480.325 person
years of follow up, and found that the ankle–brachial
index (ABI) showed an inverse linear relationship be-
tween subclinical peripheral arterial disease (PAD) and
cardiovascular disease, even at ABI values between 0.91
and 1.00 [7]. The authors also found that the risk of
death for different levels of ABI, compared with a refer-
ence ABI score of 1.11 to 1.20, formed a reverse J-
shaped curve. For levels of ABI below 1.11, the hazard
ratios (HRs) increased with decreasing ABI, and for
ABI >1.40 the HRs also increased, but this was not the
case for ABI scores between 1.11 and 1.40 [7]. However,
little is known about the relationship between ABI and
activities of daily living functioning at the population
level. In some subgroups of subjects with high cardio-
vascular risk, PAD and severe renal impairment [8–10],
there was a positive association between ABI and
HRQL, including for patients whose ABI was in the
range 0.9 to 1.3. A worse quality of life was also found
in subjects with ABI > 1.4 [11]. The subgroup of pa-
tients with intermediate cardiovascular risk is the group
in which the highest number of cardiovascular events
occur, and it is known the association of these with a
worse HRQL [12, 13]. However, the potential influence
of ABI on HRQL, when considering ABI as a continu-
ous variable, in individuals with intermediate cardiovas-
cular risk and ABI in the normal range [14] has not
been analyzed. Knowing this relationship may lead to
improvements in a multidimensional therapeutic ap-
proach for this very large subjects group at risk for a
cardiovascular event.
Vascular function, as evaluated by pulse wave velocity
(PWV) [15, 16], has been correlated with morbidity and
mortality both in patients with cardiovascular disease
and in healthy individuals. The cardio-ankle vascular
index (CAVI) is a parameter [17] of the overall stiffness
of the artery from the aorta's origin to the ankle. It can
be used to estimate the risk of atherosclerosis [18]. The
relationship between vascular function and HRQL has
been little studied, and only in some population sub-
groups. Bruner et al. [19] found a negative relationship
between the PWV and the physical component of quality
of life, as assessed by the SF-36 in an English-speaking
general population. Likewise, Crilly et al. [20] showed a
positive association between the Stanford disability index
questionnaire and the augmentation index (AIx) in pa-
tients with rheumatoid arthritis who were free of overt
arterial disease. However, we are unaware of any study
focusing on the relationship between CAVI and HRQL.
These vascular function measures are newly developed
and evaluate the early stages of atherosclerosis, and have
not been studied in subjects with intermediate cardio-
vascular risk. An important implication is whether or
not subclinical vascular lesions detected in the early
stages of atherosclerotic process affects quality of life, in
order to inform the planning of a new therapeutic ap-
proach once the alteration of vascular function has been
detected. Therefore, the aim of this study is to analyze
the relationship of vascular structure and function as
assessed by ABI, CAVI, PWV and AIx with HRQL as




The MARK study [21] is a cross-sectional study to
evaluate if ABI, CAVI, postprandial glucose, glycosyl-
ated hemoglobin, self-measured blood pressure, and co-
morbid conditions are independently associated with
incidences of vascular events, and whether they can im-
prove the predictive capacity of current risk equations
in an intermediate risk population. The second step will
occur at five and 10 years follow-up to evaluate cardio-
vascular morbidity and mortality. The current study an-
alyzed 303 subjects who were included and evaluated
the HRQL.
Study population
The population consisted of individuals between 35 to
74 years of age who had intermediate cardiovascular
risk, which was defined as coronary risk between 5 and
15 % at 10 years according to the Adaptation of the
Framingham-Wilson coronary risk equation (REGICOR)
[22] or vascular mortality risk between 1 % and 5 % at
10 years according to the SCORE equation [23] or
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moderate risk according to the 2013 European Society of
Hypertension guidelines for the management of arterial
hypertension [24]. Exclusion criteria included terminal
illness, institutionalization at the appointment time, or a
personal history of atherosclerotic disease. Sample selec-
tion was performed with a random sampling of the study
population that matched the inclusion criteria. Recruit-
ment and data collection were performed from July 2011
to June 2013. The quality of life questionnaire was per-
formed in the last 314 of the 500 subjects recruited in
Salamanca. Eleven patients were excluded because they
did not have CAVI values or had an ABI <0.9 or > 1.4.
Thus, 303 subjects were analyzed.
A sample-size calculation indicated that the 303 pa-
tients included in the study constituted a sufficient sam-
ple to detect a five point difference in the standardized
physical or mental component of the SF-12 between the
three categories of CAVI, which is considered a clinic-
ally important difference (CID) according Parker SL et
al. [25]. We considered a common standard deviation
of 10 points, with a level of significance of 95 % and a
power of 80 % in a two-sided test. Parker SL et al. [25]
found a CID of 4.7 and 8.1 points in the SF-12 for the
MCS-12 and PCS-12, respectively. We used the EPI-
DAT 4.0 software to perform this calculation.
The study was approved by an independent ethics
committee from the Salamanca health area (Spain), and
all participants gave written informed consent accord-
ing to the general recommendations of the Helsinki
Declaration [26].
Measurements
A detailed description has been published elsewhere re-
garding how the clinical data, drugs therapy, anthropo-
metric measurements, and analytical parameters were
obtained from patients [18].
Health-related quality of life (HRQL)
HRQL was assessed with the Spanish version of the SF-
12v.2, which has been validated [3, 6]. The SF-12 is a
shorter version of the SF-36 questionnaire [27], and in-
cludes 12 items, with 3 to 5 response categories placed
on a Likert scale. The SF-12 questionnaire is self-
administered and was developed to measure eight di-
mensions of HRQL: Physical Functioning, Role Physical,
Body Pain and General Health scales, Vitality, Role Emo-
tional, Social Functioning, and Mental Health. These
eight dimensions can be aggregated into two summary
measures: a physical component summary (PCS-12) and
a mental component summary (MCS-12). To estimate
the summary components of the SF-12 (i.e., PCS-12 and
MCS-12), we calculated the algebraic sum of the stan-
dardized scores of the eight dimensions (z scores)
weighted by weights (see supplementary material). The
Physical and Mental Health Composite Scores (PCS-12 &
MCS-12) are computed using the scores of the 12 ques-
tions and range from 0 to 100, where a zero indicates the
lowest level of health measured by the scales and 100 indi-
cates the highest level of health Additional file 1: Table S1
[28]. The values are standardized to a United States norm
with a mean of 50 and a standard deviation of 10. Thus,
the SF-12 summaries compare the scores for each study
participant against the mean score in the population. A
higher score in the PCS-12 or the MCS-12 corresponds to
better health status. The two standardized summary
scores provide a concise approximation of the physical
and mental components of HRQL [28].
Vascular assessment
The ankle/brachial index (ABI), cardio ankle vascular
index (CAVI), and brachial ankle pulse wave velocity
(ba-PWV) were measured using a VaSera VS-1500® de-
vice (Fukuda Denshi). The ABI was calculated automat-
ically for each foot by dividing the systolic blood
pressure (SBP) in the ankle by the SBP in the arm. An
ABI less than 0.9 or greater than 1.4 was considered ab-
normal [14]; these patients were excluded. CAVI inte-
grates the cardiovascular elasticity derived from the
aorta to the ankle pulse velocity through an oscillo-
metric method. Itis a good measure of vascular stiff-
ness, and it does not depend on blood pressure (BP)
[29]. The CAVI values were automatically calculated by
substituting the stiffness parameter β in the following
equation to detect the vascular elasticity and the heart-
ankle PWV: Stiffness parameter β = 2ρ × 1/(Ps –Pd) × ln
(Ps/Pd) × ha-PWV2, where ρ is the blood density, Ps
and Pd are SBP and diastolic blood pressure (DBP) in
mmHg, respectively, and the ba-PWV is measured be-
tween the aortic valve and the ankle. The average coef-
ficient of the variation of the CAVI is less than 5 %,
which is small enough for clinical use and confirms that
the CAVI has favorable reproducibility [30]. The CAVI
was measured at rest and was considered normal when
CAVI < 8, borderline if CAVI ≥8 or < 9, or abnormal
with suspicion of subclinical atherosclerosis if CAVI ≥9.
The ba-PWV was estimated using the following equa-
tion: ba-PWV = (0.5934 × Height (cm) + 14.4724)/tba,
where tba is the time difference between the time when
pulse waves were transmitted to the brachium and the
time when these same waves were transmitted to the
ankle [31]. A ba-PWV ≥17.5 m/s was considered abnor-
mal [32]. We used the highest CAVI and ba-PWV and
the lowest ABI obtained from right or left measurements.
The Augmentation Index (AIx) was estimated using
an oscillometric Mobil-O-Graph (Stolberg, Germany)
[33]. The measurements of central SBP (cSBP) and per-
ipheral SBP (pSBP) were taken in the dominant arm.
Arm circumference was measured and recorded to allow
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for the correct choice of cuff size (two sizes available:
24–34 and 32–42 cm). With a conventional cuff, the de-
termination of the cSBP is based on an oscillometric BP
measurement and uses the pulse waves assessed at the
brachial artery. After estimating the pBP, the cuff instantly
re-inflates and recordings of the cSBP are performed at
DBP levels for 10 s [34]. From the morphology of the aor-
tic wave, the AIx was estimated using the following for-
mula: increase in central pressure × 100/pulse pressure.
The values were adjusted to a heart rate of 75 (AIx_75) by
the Mobil-O-Graph device [33].
Lifestyle health behavior variables
Smoking
Smoking history was assessed through questions about
the participant’s smoking status (smoker/non-smoker).
We considered smokers to be subjects who currently
smoke or who stopped smoking less than one year ago.
Alcohol
Alcohol consumption was assessed through a structured
questionnaire and was expressed in grams per week.
Physical activity
Leisure time physical activity (LTPA) practices were col-
lected with the Minnesota LTPA questionnaire, which
has been validated for Spanish men and women [35, 36].
The questionnaire was administered by trained inter-
viewers and collected detailed information about phys-
ical activity (PA) in the preceding year, the number of
times this activity was performed, and the average dur-
ation of each activity on each occasion. Each PA has an
intensity code based on the ratio between the metabolic
rate during PA practice and the basal metabolic rate. We
assumed that 1 MET (basal metabolic equivalent) ap-
proximately corresponds to 1 kcal/(kg x hour) of energy
expenditure, which allowed us to calculate the total en-
ergy expenditure in leisure time PA in kilocalories per
week. Consumption (MET-min) was estimated over
14 days by multiplying the MET in physical activity by
the duration (in minutes) and cumulative frequency in
the month prior to the interview.
Diet assessment
Diet was evaluated by the Diet Quality Index (DQI) [37].
The DQI includes 18 food groups divided into three cat-
egories of consumption, with the exception of alcoholic
beverage consumption. Daily intake of one portion of
foods in the first food category is scored with two points;
lower and higher intake portions are scored with one
and three points, respectively. Daily consumption of one
alcoholic drink (i.e., 1 bottle of beer, 1 glass of wine, or 1
cup of liquor equivalent to approximately 12 g of alco-
hol) is scored with three points; lower and higher intakes
are scored 1. Consumption of foods considered detri-
mental (i.e., in the second food group category) is scored
with two points if frequency occurs between four and
six times per week; greater and lower frequent consump-
tion patterns are scored at one and three points, respect-
ively. High consumption (i.e., four or more times per
week) of food items considered beneficial (i.e., in the
third food group category) are scored with three points,
whereas intake of two to three times per week and less
than twice a week are scored with two and one points,
respectively. All food item scores are added up. The total
possible score ranges from 18 to 54.
Others measurements
Anthropometric measurements
Body mass index (BMI) was calculated as weight (kg) di-
vided by height squared (m2). A value >30 kg/m2 was
defined as obese.
Office blood pressure
Office BP was calculated as the average of the last two
of three measurements of SBP and DBP, made with a
validated sphygmomanometer (OMRON Model M10-
IT). Measurements were made on the dominant arm
while participants were in a seated position after at
least five minutes, with a cuff of appropriate size as
determined by measurement of the upper arm circum-
ference and following the recommendations of the
European Society of Hypertension [38]. Mean arterial
pressure (MAP) was calculated as the sum of the SBP
and twice the DBP, divided by three.
Laboratory determinations
Venous blood sampling was performed between 08:00
and 09:00, after the individuals had fasted and abstained
from smoking, alcohol, and caffeinated beverages for
the previous 12 h. Fasting plasma glucose, hemoglobin
A1c (HbA1c), creatinine, total cholesterol, as well as
triglyceride and high-density lipoprotein (HDL) choles-
terol concentrations were measured using standard en-
zymatic automated methods. Low-density lipoprotein
(LDL) cholesterol was estimated by the Friedewald
equation. Atherogenic index was estimated by total
cholesterol/HDL-cholesterol. All assessments were
made within a period of 10 days.
Statistical analysis
Continuous variables were expressed as the mean ±
standard deviation for normally distributed continuous
data. The median (interquartile range: IQR) was used
for asymmetrically-distributed continuous data, and the
frequency distribution was used for categorical data.
Statistical normality was tested using the Kolmogorov–
Smirnov test. The student’s t-test was used to contrast
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HRQL dimensions by gender. Pearson’s correlation was
performed to analyze relationships between quantitative
variables. We performed four multiple linear regression
analyses using the Multivariate General Linear Model
(GLM). The four independent variables including were
the ABI, CAVI, ba-PWV, and AIx_75. The eight SF-12
dimensions and PCS-12 and MCS-12 were the
dependent variables. The first model was an unadjusted
regression, and the second model adjusted for current
smoking status, alcohol consumption (g/week), physical
activity (METs-min 14 days), nutrition (DQI), MAP,
atherogenic index, HbA1c, as well as antihypertensive
and lipid-lowering drugs. Comparisons of the physical
and mental component between the three categories of
CAVI were performed using the multivariate analysis of
variance (MANOVA), adjusting for the same variables
of multiple linear regressions (GLM) and estimating
marginal means. The differences between groups were
assessed using the Fisher's Least Significant Difference
(LSD) post hoc test. The data were analyzed using the
Statistical Package for the Social Sciences version 20.0
(SPSS, Chicago, IL, USA). A value of p < .05 was consid-
ered statistically significant.
Results
Table 1 shows the general characteristics of the sample.
Of the 303 patients, the mean age was 60.5 ± 8.5 years;
50.5 % were women, 21 % were smokers, 76 % were
hypertensive, and 24 % were diabetic. The ABI mean
was 1.09 ± 0.07, the ba-PWV mean was 14.64 ± 2.55 m/s
with a 12.9 % of patients higher than 17.5 m/s,
theAIx_75 mean was of 26.46 ± 14.05 and the CAVI
mean was 8.61 ± 1.08 with a36.6 % higher than 9.
The mean HRQL dimensions for the sample (Table 2)
are only above the middle (50) for physical function, role
physical, and vitality. The scores for the other subscales
are close to 50except for general health, which is the
lowest (39.92 ± 8.90). Men had higher scores on all di-
mensions except general health and vitality. They also
had higher scores on the PCS-12 (49.9 vs. 46.9, p =
0.004) and MCS-12 (51.2 vs. 47.7, p = 0.003).
Age was positively correlated with CAVI (r = 0.547), ba-
PWV (r = 0.469), and AIx_75 (r = 0.255), (p < 0.01). The
relationship was similar with the general health (r = 0.117),
social functioning (r = 0.147), mental health (r = 0.148),
and MCS-12 (r = 0.147), (p < 0.05). However, the rela-
tionship did not reach statistical significance for ABI
(r = 0.051) or PCS-12 (r = 0.013).
The multiple linear regressions (Table 3 and Additional
file 2: Table S2) considered the dimensions of quality of
life as dependent variables. The unadjusted model 1 shows
a positive relationship between physical function, role
physical, bodily pain dimensions, and the PCS-12 with
ABI and CAVI. In addition, CAVI and ba-PWV also have
a positive association with the mental health dimension.
In the second adjusted model, the positive association of
ABI and CAVI with physical function and the PCS-12 was
maintained, and a negative association between ABI with
the MCS-12 was found (p = 0.048).
Figure 1 and Table 4 shows data from the PCS-12 and
MCS-12 in relation to the three categories of CAVI. The
data highlight a positive linear relationship between the
PCS-12 and CAVI, as well as increased marginal PCS-12




Gender (women) n (%) 153 (50.5)
Smoker n (%) 64 (21.1)
Alcohol drinking (g/week) 30 0–90
METs-min/14 days 3536.56 3395.87
Diet quality index 31.30 2.73
Systolic blood pressure (mmHg) 132.96 15.80
Diastolic blood pressure (mmHg) 80.13 10.26
Mean blood pressure (mmHg) 97.74 10.91
Heartrate (bpm) 64.60 10.20
Total Cholesterol (mg/dl) 220.60 38.40
LDL Cholesterol (mg/dl) 139.09 34.26
HDL-Cholesterol (mg/dl) 56.43 14.20
Triglycerides (mg/dl) 106 78–144
Atherogenic index 4.13 1.19
Glycaemia (mg/dl) 88 91–98
HbA1c % 5.6 5.4–6.0
Creatinine (mg/dl) 0.85 0.18
ABI 1.09 0.07
ba-PWV (m/s) 14.64 2.55
ba-PWV > 17.5 m/s n (%) 39 (12.9)
CAVI 8.61 1.08
CAVI categories. n (%) <8 90 (29.7)
8–9 102 (33.7)
>9 111 (36.6)
AIx_75 % 26.46 14.05
Hypertensive patients n (%) 230 (75.9)
Diabetic patients n (%) 73 (24.1)
Obesity patients n (%) 81 (26.7)
Antihypertensive drugs n (%) 146 (48.2)
Antidiabetic drugs n (%) 41 (13.5)
Lipid lowering drugs n (%) 107 (35.3)
METs Metabolic equivalent, Atherogenic index: Total Cholesterol/HDL-Cholesterol,
ABI Ankle brachial index, ba-PWV Brachial-Ankle Pulse Wave Velocity. CAVI Cardio
Ankle Vascular index, AIx_75 Augmentation Index adjusted 75 bpm, SD Standard
Deviation, IQR Interquartile Range
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means as CAVI increases. This is not the case for the
MCS-12, either in the unadjusted or adjusted model.
Discussion
In a sample of subjects with intermediate cardiovascular
risk and an ABI score between 0.9 and 1.4, we found a
positive association between ABI and the physical di-
mensions of HRQL; the higher ABI, the better the pa-
tient’s quality of life in the physical dimension. T his
positive association was maintained with physical func-
tion dimension, the PCS-12, and the MCS-12after
adjusting for potential confounders. We found no rela-
tionship, after adjustments, between the ba-PWV and
any of the dimensions of quality of life. However, we
found an inverse unadjusted relationship between the
physical function dimension and the AIx_75, and this re-
lationship achieved borderline significance after adjust-
ing (p = 0.052). This finding suggests that higher AIx_75
would be associated with worse quality of life in the
physical function dimension. CAVI has a positive rela-
tionship with HRQL in the physical dimensions. This is
true even after adjusting for confounding factors, includ-
ing physical function and PCS-12. That is, a higher
CAVI value was associated with better HRQL in the
physical dimensions and in the PCS-12.
These discrepancies between the ABI and CAVI re-
sults could be explained by the different phases of vascu-
lar aging that are evaluated by these parameters. CAVI
Table 2 Health related quality of life dimensions (SF-12) by sex
Global Women Men p
Mean SD Mean SD Mean SD
Standardized physical function 50.80 ± 8.92 49.17 ± 9.49 52.46 ± 8.00 0.001
Standardized role physical 50.96 ± 9.13 49.41 ± 9.66 52.54 ± 8.29 0.003
Standardized bodily pain 49.88 ± 11.58 46.72 ± 12.63 53.10 ± 9.40 <0.001
Standardized general health 39.92 ± 8.90 39.24 ± 9.18 40.60 ± 8.59 0.185
Standardized vitality 50.90 ± 11.13 49.85 ± 10.99 51.98 ± 11.20 0.097
Standardized social functioning 49.90 ± 9.72 48.38 ± 10.28 51.45 ± 8.89 0.006
Standardized role emotional 48.94 ± 9.68 47.31 ± 9.95 50.60 ± 9.13 0.003
Standardized mental health 49.67 ± 10.42 47.01 ± 10.04 52.39 ± 10.12 <0.001
Standardized physical component 48.42 ± 9.32 46.90 ± 10.50 49.97 ± 7.66 0.004
Standardized mental component 49.44 ± 10.45 47.66 ± 10.78 51.24 ± 9.82 0.003
P values estimated by T-Student test. SD Standard Deviation
Table 3 Multiple linear regression analysis of vascular structure and function parameters and health-related quality of life
Model 1: Unadjusted Model2: Fully adjusted
B CI 95 % p B CI 95 % p
ABI
Standardized physical component 24.46 10.40 to 38.52 0.001 23.90 8.24 to 39.55 0.003
Standardized mental component 1.53 −14.55 to 17.61 0.852 −17.43 −34.67 to −0.19 0.048
CAVI
Standardized physical component 1.50 0.54 to 2.46 0.002 1.59 0.32 to 2.85 0.014
Standardized mental component 0.81 −0.28 to 1.90 0.145 −0.72 −2.11 to 0.67 0.310
PWV
Standardized physical component 0.19 −0.22 to 0.61 0.361 0.01 −0.53 to 0.52 0.993
Standardized mental component 0.29 −0.18 to 0.75 0.226 −0.08 −0.65 to 0.50 0.791
AIx_75
Standardized physical component −0.08 −0.15 to 0.01 0.039 −0.08 −0.17 to 0.01 0.059
Standardized mental component 0.02 −0.06 to 0.11 0.625 0.06 −0.03 to 0.16 0.183
Multiple linear regression analysis by Multivariate General lineal model (GLM). Dependent variables: Standardized Physical Component and Standardized
Mental Component
Independent Variables: Ankle brachial index (ABI), Cardio Ankle Vascular index (CAVI), Brachial-Ankle Pulse Wave Velocity (ba-PWV) and Augmentation
index (AIx_75)
Model 1: Unadjusted; Model 2: Adjusted for age, gender, current smoker, alcohol consumption in gr/week physical exercise (METs-min 14 days), diet quality index,
mean blood pressure, atherogenic index (Total Cholesterol/HDL-Cholesterol), HbA1c and antihypertensive and lipid-lowering drugs
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alteration begins in the early stages of vascular aging, in
which only the functional component is affected and the
structure might still be normal. However, the ABI princi-
pally evaluates the vascular structure that affects more
late phases. This could provide a possible explanation
for the observation that quality of life is affected by ABI
deterioration, because it reflects a more advanced stage
of the atherosclerotic process. CAVI principally evaluates
vascular function, in particular early impairment that
has not yet affected quality of life.
Few studies to date have analyzed the relationship be-
tween ABI with the quality of life. Nevertheless, Long et
al. [9] found a greater association between HRQL and
PAD symptoms than with ABI values. However, Korho-
nen et al. [8] found that the HRQL of individuals with
asymptomatic or borderline PAD was worse than in the
subjects with normal ABI. Likewise, they concluded that
the level of ABI is independently related to physical
functioning. In the same line, Chen et al. [10] conducted
a cross-sectional study with chronic hemodialysis pa-
tients and found that quality of life scores were posi-
tively and linearly associated with ABI values in patients
with an ABI score below 0.9. This trend was also linear
with an increase of the slope in patients with an ABI be-
tween 0.9 and 1.3. However, it became a negative for pa-
tients with an ABI score greater than 1.3. They
concluded that ABI is not only an indicator of PAD but
is also positively associated with quality of life [10].
These results are consistent with our findings.
Therefore, this study offers additional evidence for the
relationship between ABI and quality of life in a large
group of subjects with intermediate cardiovascular risk.
a
b
Fig. 1 Marginal means of standardized physical (PCS-12) and mental (MCS-12) components by CAVI categories. P < 0.05 by Multivariate General
Lineal Model (MANOVA) using LSD post hoc test. Unadjusted: PCS-12: CAVI < 8 with > 9. MCS-12: CAVI 8–9 with > 9. Adjusted: PCS-12: CAVI < 8
with > 9. MCS-12: CAVI < 8 with 8–9 and 8-9 with > 9. Adjusted for age, gender, current smoker, alcohol consumption in gr/week, physical activity
(METs-min 14 days), diet quality index, mean blood pressure, atherogenic index (Total Cholesterol/HDL-Cholesterol), HbA1c and antihypertensive
and lipid-lowering drugs. CAVI: Cardio Ankle Vascular index, SE: Standard error
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We have no clear interpretation for the negative associ-
ation, albeit at the limit of statistical significance, be-
tween ABI and the mental component of quality of life,
and we cannot exclude it is a spurious association.
The association of vascular function with the quality
of life has been less studied. Kidher et al. [39] found an
association of the PWV with the quality of life in pa-
tients with severe aortic valve disease. Brunner et al. [19]
found a negative correlation of carotid femoral PWV
(cf-PWV) with the physical component of quality of
life, as assessed by the SF-36 in an UK cohort. In our
study, we only found a positive association of ba-PWV
with physical and mental health; however, this relation-
ship disappears when the model is adjusted for age and
sex. The different methodologies used to calculate the
PWV can influence the results between different studies.
Crilly et al. [20] studied rheumatoid arthritis patients
and analyzed the relationship between quality of life (as
measured by the Stanford Health Assessment Question-
naire disability index [40]) and AIx_75, and found a
positive association between the two indexes that
remained even after adjusting for potential confounders.
The direction of the relationship of AIx_75 with the
quality of life in our work in a population with inter-
mediate cardiovascular risk is the same as that found by
Crilly, although the association lost significance after
adjusting for potential confounders. This difference
might be attributable to the differences in study popula-
tions between the two studies.
We found an association between CAVI and the fol-
lowing dimensions: physical function, role physical, bod-
ily pain, general health, mental health, and the PCS-12.
After adjustment, the association only remained for the
physical function dimension and the PCS-12. It is not
clear why we noted a relationship between vascular
function (as evaluated by CAVI) and quality of life (as
assessed by the SF-12). Quality of life was found to be
higher in men along most dimensions; age had a positive
correlation with CAVI and some dimensions of quality
of life, especially the mental component. The association
of age and gender with quality of life and CAVI could
be influencing the relationship between these two vari-
ables, but as shown in the second regression model, the
associations persisted after adjusting for the above-
mentioned variables.
Other possible variables that could mediate the rela-
tionship, such as lifestyle health behaviors, cardiovascu-
lar risk factors, or certain drugs, were included in the
adjusted regression model, yet the association between
CAVI and physical function remained even after adjust-
ing for these potential mediators. When we conducted a
literature review we did not find studies analyzing this
relationship, and thus further studies are needed to con-
firm these findings.
Limitations
The main limitation of this study was the use of cross-
sectional data, which prevented us from establishing a
temporal relationship between different parameters that
assess vascular structure and function and HRQL. We
must also bear in mind that the quality of life question-
naires have a subjective component that can influence
the results. However, this is the first study to examine
the relationship between ABI, ba-PWV, AIx_75, and
CAVI with HRQL in adults with intermediate cardiovas-
cular risk and normal ABI.
Conclusions
For patients with ABI in the normal range, we found a
positive association between the physical function di-
mension and the PCS-12 of HRQL; i.e., a higher ABI is
associated with improved quality of life. The CAVI data
also showed a positive association with the PCS-12, indi-
cating that a more unfavorable CAVI was associated
with improved quality of life. More studies are needed to
clarify these findings and to assess whether vascular
structure and function have different relationships with
quality of life, or whether the results may be influenced
by the subjective nature of the SF-12.
Ethical approval and consent
The study was approved by an independent ethics com-
mittee from the Salamanca health area (Spain), and all
participants gave written informed consent according to
the general recommendations of the Helsinki Declaration.
Table 4 Marginal means of standardized physical and mental
components by CAVI categories
Unadjusted Fully adjusted
CAVI Mean ± SE Mean ± SE
Standardized Physical Component <8 46.51 ± 0.97* 45.21 ± 1.27*
8–9 48.36 ± 0.91 47.57 ± 1.06
> = 9 50.03 ± 0.88* 49.24 ± 1.08*
Standardized Mental Component <8 49.22 ± 1.09 50.49 ± 1.38
8-9 47.23 ± 1.02* 45.21 ± 1.27*
> = 9 51.64 ± 0.98* 47.57 ± 1.06*
*P by Multivariate General Lineal Model (MANOVA) using LSD post hoc test.
Unadjusted: Physical Component, CAVI < 8 with 8–9, p = 0.167; CAVI < 8 with >
9, p = 0.008; CAVI 8–9 with > 9, p = 0.190. Mental Component: CAVI < 8 with 8–
9, p = 0.183; CAVI < 8 with > 9, p = 0.101; CAVI 8–9 with > 9, p = 0.002. Adjusted:
Physical Component, CAVI < 8 with 8–9, p = 0.123; CAVI < 8 with > 9, p = 0.017;
CAVI 8–9 with > 9, p = 0.226. Mental Component: CAVI < 8 with 8–9, p = 0.009;
CAVI < 8 with > 9, p = 0.608; CAVI 8–9 with > 9, p = 0.023
Adjusted for age, gender, current smoker, alcohol consumption in g/week,
physical exercise (METs-min 14 days), diet quality index, mean blood pressure,
atherogenic index (Total Cholesterol/HDL-Cholesterol), HbA1c and
antihypertensive and lipid-lowering drugs, CAVI Cardio Ankle Vascular index,
SE Standard error.
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